INTRODUCTION: Wilms tumor gene 1 (WT1) contributes to uterine sarcoma tumor biology. In this study, we aimed to clarify the prognostic value of WT1. METHODS: A retrospective clinical and histopathological review of 71 women with high-grade uterine sarcoma (leiomyosarcoma [n = 24], undifferentiated sarcoma [n = 9]), and carcinosarcoma (n = 38) was performed. Patients were followed up for at least 12 months. Wilms tumor gene 1 expression was determined by immunohistochemistry. Data on recurrence (progression-free survival) and overall survival (OS) were available for all patients. Univariate and multivariate analyses of WT1 expression were carried out using Kaplan-Meier curves and Cox regression, respectively. RESULTS: Forty-nine (69%) tumors were WT1 positive. Forty-seven (66%) patients died of the disease, with a median OS time of 22 months. Wilms tumor gene 1 was a predictor of survival in the univariate analysis: the hazard ratio of WT1 positivity was 2.44 (95% confidence interval, 1.34-4.71) for progression-free survival and 2.48 (95% confidence interval, 1.26-4.90) for OS. Multivariate analysis including stage, age, tumor size, and sarcoma subtype identified only stage and WT1 positivity as independent prognostic markers for survival. CONCLUSIONS: The identification of WT1 as a prognostic marker confirms its role in high-grade uterine sarcoma and carcinosarcoma tumor biology.
INTRODUCTION:Wilms tumor gene 1 (WT1) contributes to uterine sarcoma tumor biology. In this study, we aimed to clarify the prognostic value of WT1. METHODS: A retrospective clinical and histopathological review of 71 women with high-grade uterine sarcoma (leiomyosarcoma [n = 24], undifferentiated sarcoma [n = 9]), and carcinosarcoma (n = 38) was performed. Patients were followed up for at least 12 months. Wilms tumor gene 1 expression was determined by immunohistochemistry. Data on recurrence (progression-free survival) and overall survival (OS) were available for all patients. Univariate and multivariate analyses of WT1 expression were carried out using Kaplan-Meier curves and Cox regression, respectively. RESULTS: Forty-nine (69%) tumors were WT1 positive. Forty-seven (66%) patients died of the disease, with a median OS time of 22 months. Wilms tumor gene 1 was a predictor of survival in the univariate analysis: the hazard ratio of WT1 positivity was 2.44 (95% confidence interval, 1.34-4.71) for progression-free survival and 2.48 (95% confidence interval, 1.26-4.90) for OS. Multivariate analysis including stage, age, tumor size, and sarcoma subtype identified only stage and WT1 positivity as independent prognostic markers for survival. CONCLUSIONS: The identification of WT1 as a prognostic marker confirms its role in high-grade uterine sarcoma and carcinosarcoma tumor biology.
Authors: Ahrong Kim; Eun Young Park; Kyungbin Kim; Jeong Hee Lee; Dong Hoon Shin; Jee Yeon Kim; Do Youn Park; Chang Hun Lee; Mee Young Sol; Kyung Un Choi; Jeung Il Kim; In Sook Lee Journal: World J Surg Oncol Date: 2014-07-16 Impact factor: 2.754
Authors: Todd L Edwards; Ayush Giri; Jacklyn N Hellwege; Katherine E Hartmann; Elizabeth A Stewart; Janina M Jeff; Michael J Bray; Sarah A Pendergrass; Eric S Torstenson; Jacob M Keaton; Sarah H Jones; Radhika P Gogoi; Helena Kuivaniemi; Kathryn L Jackson; Abel N Kho; Iftikhar J Kullo; Catherine A McCarty; Hae Kyung Im; Jennifer A Pacheco; Jyotishman Pathak; Marc S Williams; Gerard Tromp; Eimear E Kenny; Peggy L Peissig; Joshua C Denny; Dan M Roden; Digna R Velez Edwards Journal: Front Genet Date: 2019-06-12 Impact factor: 4.599
Authors: Hatice U Osmanbeyoglu; Fumiko Shimizu; Angela Rynne-Vidal; Direna Alonso-Curbelo; Hsuan-An Chen; Hannah Y Wen; Tsz-Lun Yeung; Petar Jelinic; Pedram Razavi; Scott W Lowe; Samuel C Mok; Gabriela Chiosis; Douglas A Levine; Christina S Leslie Journal: Nat Commun Date: 2019-09-25 Impact factor: 17.694